Clinical-stage partner Herantis is a clinical-stage biotech focused on disease-modifying therapies for Parkinson's disease with the lead candidate HER-096 advancing to Phase 2 in 2026 and plans for results in H1 2029, presenting a potential long-term collaboration window for CROs, trial design consultants, and translational science partners.

Regulatory and trials Recent CRO engagement and leadership appointments indicate active clinical trial execution and regulatory readiness. Target opportunities include clinical trial services, biomarker strategy, and real-world data partnerships to support Phase 2a/2b expansion and potential registries.

Funding runway With substantial funding secured to advance HER-096 and ongoing biomarker projects, there is an opportunity to offer supplementary funding advisory, grant alignment services, and cost-optimization consulting to accelerate development timelines.

Diagnostics & detection Upcoming collaborations around early detection of Parkinson’s disease with Indivi AG suggest a market need for diagnostic/biomarker support, enabling partnerships in companion diagnostics, screening programs, and liquid biopsy development.

External engagement Active conference presence and strategic partnerships with biotech investors indicate a favorable environment for contract research, consulting, and patient recruitment networks, offering sales opportunities in CRO coordination, site networks, and patient engagement platforms.